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Bladder tumour tissues and corresponding uninvolved mucosa (normal tissue) of Egyptian bladder cancer patients were assessed
for O6-alkylguanine-DNA-alkyltransferase (MGMT) activity by functional assay of tissue extracts (36 paired samples), and
distribution by immunoﬂuorescence (IF) microscopy of ﬁxed material (24 paired samples). MGMT varied widely from 42–
253fmoles/mgproteinandfrom3.2–40fmoles/µgDNAinnormaland58–468fmoles/mgproteinand2.5–49.5fmoles/mgprotein,
in the tumour tissues; only one tumour had undetectable activity. Pairwise comparison of MGMT activity in tumour and adjacent
normal tissue showed no signiﬁcant diﬀerence based on DNA content but was 1.75-fold higher in tumour (P<. 01) based on
protein. There was no eﬀect of gender or bilharzia infection status. IF showed that in tumours, both the mean percentage of
positive nuclei (57.3 ± 20.3%) and mean integrated IF (5.47 ± 3.66) were signiﬁcantly higher than those in uninvolved tissues
(42.8 ± 13.5% P = .04) and (1.89 ± 1.42; P<. 01), respectively. These observations suggest that, overall, MGMT levels are
increased during human bladder carcinogenesis and that MGMT downregulation is not a common feature of bladder cancers.
Based on this, bladder cancers would be expected to be relatively resistant to chemotherapy which involved O6-guanine alkylating
antitumour agents.
1.Introduction
Carcinoma of the urinary bladder is the most common
malignancy among Egyptian males, accounting for 16% of
total cancer incidence while in females it ranks second to
breast cancer [1, 2]. The high incidence of bladder cancer
in Egypt is associated with chronic urinary infection with
Schistosoma haematobium [2, 3] which is thought to lead
to endogenous nitrosation and the formation of N-nitroso
compounds [4–6]. Such compounds have been shown to
alkylate DNA causing a range of DNA adducts with diﬀering
mutagenic, and carcinogenic potential [7]. O6-alkylguanine
is one such adduct which has been shown to be a toxic,
mutagenic and carcinogenic lesion. This damage can be
processed by the DNA repair protein, O6-alkylguanine-
DNA-alkyltransferase (MGMT), which transfers the alkyl
grouptoacysteineresidueatitscatalyticsiteinaprocessthat
leads to the inactivation of the protein. Since each MGMT
moleculeactsonlyonce,cellshavealimitedcapacitytorepair
O6-alkylguanine lesions, which is determined by the steady
state number of MGMT molecules at the time of alkylating
agent exposure. Further repair following depletion of the
pool requires de novo synthesis of the protein [8, 9].
While MGMT may be an important factor in the
aetiology of bladder cancer, it may also play an important
role in cellular defence against the toxic eﬀects of certain
types of alkylating agents used in cancer chemotherapy,
usually referred to as O6-alkylating agents [10, 11]. In this
context, cytosine methylation of the MGMT promoter has
generallybeenacceptedtoresultinlossofMGMTexpression
[12, 13] ,b u tt h i si sr e p o r t e dt ob er a r ei nb l a d d e rt u m o u r s
occurring in 2–9% of those examined [14, 15]. Tumour2 Journal of Nucleic Acids
MGMT activity has also been reported to be higher [16]o r
lower [4] than normal bladder tissue. The reasons for these
conﬂictingresultsarenotclearbutmayreﬂecttheunderlying
pathogenesis of bladder cancer or the use of normal bladder
tissue from diﬀerent patients as controls instead of the
corresponding uninvolved mucosa from the same subject.
Studies of tumour extracts also give no indication of possible
regionalheterogeneityorintracellularlocalisationofMGMT.
We have therefore determined the distribution and levels
of immunoreactive MGMT and MGMT activity in human
bladder tumour tissues and corresponding uninvolved
mucosa using immunohistochemistry and a functional assay
for MGMT activity. The results were examined in relation to
tumour type, gender, and schistosomiasis status. There was
no signiﬁcant diﬀerence in activity between samples from
men and women and from those with or without evidence
of bilharzia infection. But overall, tumour samples displayed
higher levels of MGMT expression than associated normal
tissues.
2.MaterialsandMethods
2.1. Human Tissue Specimens. Tissue samples were collected
during radical cystectomy of 36 Egyptian bladder cancer
patients attending the department of Urology, Faculty of
Medicine, Alexandria University following taking informed
consent and ensuring non compromise of pathologic diag-
nosis. All samples were taken from the urinary face of the
bladder mucosa and were frozen immediately on dry ice
and stored at −70
◦C. Samples were collected, in pairs, each
pair comprised a sample of bladder tumour and a sample
of bladder mucosa with no macroscopic sign of tumour
invasion (referred to as uninvolved tissue). Schistosomiasis
infection was established from a self-reported clinical history
ofschistosomiasisorschistosomaovadetectedinhistological
specimens. Most (32) patients had evidence of bilharzia
infection: 23 had a transitional cell carcinoma (TCC), 5
a squamous cell carcinoma (SCC), and 4 a TCC with
SCC foci; of the four patients without infection, 2 had
adenocarcinomas (Ad), 1 a SCC, and 1 a TCC with SCC foci.
2.2. Assay of Tissue Levels of MGMT. MGMT activity in
bladdertissueextractswasassayedinall36pairedsamplesby
measuring the transfer of [3H] from a [3H]-methylatedDNA
substrate to protein in the tissue extract using the methods
describedbyWatsonandMargison[17].MGMTactivitywas
e x p r e s s e da sf m o l e so fm e t h y lg r o u p st r a n s f e r r e dp e rm go f
protein and per µg of DNA in the tissue extract. MGMT
activity in paired uninvolved and tumour tissue from the
same patient were compared using a paired sample t-test.
2.3. Tissue Localisation of Human MGMT. Frozen bladder
t i s s u e sw e r eﬁ x e di n4 %n e u t r a lb u ﬀered formalin then
processed to paraﬃn wax. Sections (3µm) were cut and
mounted onto APES-subbed slides, dewaxed in xylene, and
rehydrated in graded ethanol. Tissues were then microwaved
(650 watts) in 10mM citrate buﬀer (pH 6.0) to retrieve
the immunoreactivity of the cross-linked proteins. Slides
were treated with 3% H2O2 in TBS to block endogenous
peroxidase, washed in ddH2O and TBS, and incubated
with 10% normal swine serum. Sections were incubated
at 4◦C with antihuman MGMT 1◦Ab (diluted to 1:1000).
Slides were then washed in TBS, followed by application
of swine-antirabbit biotinylated IgG and ABC peroxidase.
The sections were developed with DAB/H2O2, washed,
dehydrated, and mounted. As a negative control, adjacent
sections were incubated with preimmune serum instead of
the MGMT antiserum.
2.4. Quantitative Immunohistochemistry. Quantitation of
MGMT in tissue sections was performed using immunoﬂu-
oresence (IF) in 24 paired samples. Sections were stained
for MGMT as above except that the ABC complex and DAB
visualisation steps were omitted and replaced by Cy3/DAPI
ﬂuorescent staining; samples were stained with Avidin-Cy3
(1:1000) followed by TBS wash then counterstained with
DAPI (0.2 µg/ml). Samples were then washed with ddH2O
and mounted in PBS-buﬀered glycerol (9:1).
Fluorescent microscopy images of the mounted slides
were generated using a Nikon microscope equipped with a
mercury arc lamp and with red and blue ﬁlter sets (for Cy3
and DAPI ﬂuorescence resp.). Images were captured using a
Hitachi HVC20 camera and analysed with the Lucia G image
analysis software package using a macro that automated
data collection and performed calculations of the number
of positive nuclei, the mean and integrated ﬂuorescence, and
mean area.
The macro operated the following steps: (i) highlighting
the position of nuclei in tissue sections by the use of a
DAPI ﬁlter, (ii) superimposing the nuclear outline on the
Cy3 image (through TRITC ﬁlter), (iii) capturing this image
and comparing it against negative control sections, and (iv)
measuring the ﬂuorescence intensity of MGMT-Cy3 staining
and the area of each nucleus within the nuclear boundaries
recorded from the DAPI image.
For each sample, data were averaged from 10 to 20 ﬁelds
(depending on the size of the section). MGMT expression
in the tissue sections was quantiﬁed using 3 parameters: (1)
the percentage of immunoreactive MGMT positive nuclei
which indicates the fraction of cells containing detectable
levels of nuclear MGMT, (2) the mean ﬂuorescence intensity
of Cy3 MGMT staining which corresponds to the average
amount of MGMT protein per unit nuclear area in the
positively staining cells, and (3) the integrated ﬂuorescence
(area fraction of Cy3 positive nuclei x mean ﬂuorescence)
which represents the total amount of MGMT protein in
the tissue. These ﬂuorescent parameters were compared in
paired uninvolved and tumour tissue from the same patient
were compared using a paired sample t-test
3. Results
All uninvolved (normal) bladder tissue samples contained
measurable MGMT activity which ranged from 3.2 to
39.8fmoles/µg DNA (12.4-fold variation). MGMT activity
was detected in 35/36 tumour samples with the activityJournal of Nucleic Acids 3
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Figure 1: Relationships between MGMT activity (upper: fmole/mg protein, lower: fmole/ug DNA) in normal (N) and tumour (T) tissues
of Egyptian bladder cancer patients. Data are also subdivided according to gender and bilharzia status. Statistical analyses are presented in
Table 1.
Tumour histology
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Figure 2: Relationship between MGMT activity (fmole/µgo f
cellular DNA: means indicated by asterisks, error bars indicate
standard error) and tumour histology. TCC, transitional cell
carcinoma; SCC, squamous cell carcinoma; AD, adenocarcinoma.
ranging up to 49.5fmoles/µg DNA. There was no signiﬁcant
diﬀerence in activity between samples from men and women
and from those with or without evidence of bilharzia
infection (Table 1; Figure 1) or in activity from samples of
diﬀerent histological tumours (Figure 2). Tumour MGMT
activity when expressed as fmoles/mg protein was signiﬁ-
cantly higher than that in uninvolved tissue from the same
patient (Table 1). However, when MGMT was expressed as
fmole/µg DNA there was, overall, no signiﬁcant diﬀerence
between tumour and normal tissue (Table 1). Breaking this
down, tumour MGMT activity based on protein content was
1.5–5-fold higher in 22 sample pairs, 10 pairs of samples
had similar levels of activities in tumour and normal tissue,
while3tumoursampleshad1.5-foldloweractivitycompared
to uninvolved tissue. On the other hand, based on DNA
content, the MGMT activities of 9 tumour samples were
up to 3-fold higher than the corresponding controls; in
16 patients, there were similar levels, while in 10 patients
tumour samples had 1.5- to 2-fold lower activities than
control.
Representative examples of the inter- and intracellular
distribution and intensity of MGMT staining in the blad-
der sections are illustrated in Figure 3. MGMT antiserum
staining showed mild upregulation of MGMT expression
in the metaplastic epithelium (2b) in comparison with the
normal urothelium (2a). The intensity of tumour staining
showed marked variation between patients’ samples. One
SCC bladder sample (2a) showed relatively homogenous
pattern and intense nuclear staining as well as some cyto-
plasmic staining, whereas another SCC sample (moderately
diﬀerentiated and keratinised) presented a heterogeneous
pattern and less intense nuclear staining with some faint
cytoplasmic staining (2b). The invasive TCC sample showed
more intense but less uniform staining of the tumour nuclei
(3a) than did the papillary TCC sample (3b). In all cases,
no cellular staining was observed with preimmune serum
and all nuclei acquired the blue colour of the haematoxylin
counterstain. There was an obvious inconsistent pattern of
staining in the tumour tissue relative to the uninvolved
mucosa. In some of the samples, diﬀerences in the intensity
of MGMT nuclear staining were observed between normal
urothelium and the corresponding tumour tissue from the
same patient (4 and 5). While in some cases the urothelial
nuclei showed heavy staining compared to the tumour tissue
(4a) and (4b), in other cases the bladder urothelium showed
heterogeneous and generally reduced nuclear staining in
comparison to its corresponding tumour (5a) and (5b).
Twenty four paired bladder samples from the previous
series of tumour and uninvolved tissues were stained for
MGMT using IF Cy3 staining with DAPI counterstain. In
tumour tissues, there was no association between the % pos-
itive nuclei and either the mean ﬂuorescence (r = 0.10; P =
.64) or the integrated ﬂuorescence (r = 0.37; P = .21), but
there was an association between the mean and integrated4 Journal of Nucleic Acids
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Figure 3: Immunohistochemical detection of MGMT in bladder tissue from patients with bladder cancer: normal urothelium (1a) and
squamous metaplastic epithelium 1(b); SCC (2a) and moderately diﬀerentiated SCC (2b) sections of bilharzial bladder; invasive TCC (3a)
and low grade papillary TCC (3b); non neoplastic urothelium with some dysplastic changes (4a) and grade II papillary TCC (4b); normal
urothelium (5a) and invasive TCC (5b). Note that the intensity of staining is highest in the high grade section (5b). Scale bars=100µm.Journal of Nucleic Acids 5
Table 1: MGMT activity in extracts of bladder tumours and uninvolved tissue.
n
MGMT activity (mean ± SD)
Fmoles/mg protein Fmoles/µgD N A
Uninvolved
tissue
Tumour
tissue
Diﬀerence
(tumour
uninvolved)
Uninvolved
tissue Tumour tissue
Diﬀerence
(tumour
uninvolved)
Total 36 101.6 ±55.9 171.6 ±94.07 0 .0 ±75.8
∗ 16.1 ±8.21 6 .3 ±10.20 .2 ±8.5
Males 30 104.3 ±58.7 187.0±93.1 82.7 ±73.6
∗ 16.3 ±8.21 7 .3 ±10.31 .0 ±8.9
Females 6 88.5 ±40.89 4 .5 ±55.66 .0 ±54.11 5 .3 ±8.71 1 .7 ±8.9 −3.6 ±5.2
Schistosomiasis
infected 32 105.0 ±56.6 171.1 ±94.46 6 .1 ±75.6
∗ 16.2 ±8.61 6 .9 ±10.70 .7 ±8.6
Schistosomiasis
negative 47 5 .0 ±48.5 175.3 ±31.0 100.3 ±79.31 5 .8 ±4.71 1 .9 ±3.2 −4.0 ±7.3
∗P<. 001
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Figure 4: Ranges and means (asterisks, error bars indicate standard
error)inimmunoﬂuorescencevaluesforMGMTinnormal(N)and
tumour(T)tissue.Valuesforpositivenucleiareshownas%,andfor
mean ﬂuorescence and integrated ﬂuorescence as relative units.
ﬂuorescence (r = 0.45; P = .03). In contrast, in uninvolved
tissues there were signiﬁcant associations between the %
positive nuclei and both the mean ﬂuorescence (r = 0.54;
P = .006) and the integrated ﬂuorescence (r = 0.90; P<
.001) and also between the mean and integrated ﬂuorescence
(r = 0.54; P = .006). This probably reﬂects a higher degree
of heterogeneity in the tumour tissues.
The percentage of MGMT positive nuclei varied from 21
to 90% in tumour tissues, and from 15 to 73% in uninvolved
bladder tissues. The mean percentage positive nuclei for
tumours was signiﬁcantly higher (P = .002) than that for
the corresponding uninvolved tissues (Table 2; Figure 4). In
contrast, the average of the mean ﬂuorescence was signiﬁ-
cantly lower in tumours than in normal tissues (P = .004;
Table 2; Figure 4). However, integrated MGMT ﬂuorescence
varied from 0.56 to 15.43 in bladder tumours (27.6-fold
variation) and from 0.29 to 5.78 in uninvolved bladder tissue
(19.9-fold variation). The mean of this parameter was again
signiﬁcantly higher in tumours than in the corresponding
normal tissue (P<. 001 Table 2; Figure 4). There were no
diﬀerences in these parameters in tumour tissues of diﬀerent
histology (data not shown).
In normal (uninvolved) bladder tissues, MGMT activity
was correlated with the % positive nuclei and integrated
ﬂuorescence but not with the mean ﬂuorescence (Figure 5)
whereas in tumour tissue, MGMT activity was only corre-
lated with the mean ﬂuorescence (Figure 5).
MGMT activity in normal tissue was highly correlated
with that found in tumour tissue (Figure 6) whereas there
were no correlations between immunoﬂuorescence param-
eters in normal tissue and the corresponding parameters in
tumour tissue (Figure 6).
The marked variations in MGMT expression levels
within and between patient tumour samples, along with the
numbers of samples in the study, have precluded testing any
correlation between MGMT expression and other factors
such as gender and bilharzial infection.
4. Discussion
In this study, MGMT protein was measured in bladder
tissues using quantitative IF and MGMT activity using a
functional assay. A wide range in immunoreactive protein
levels was detected; not all cells were stained and in positively
stainingcellsintensityvariedbutwasmainlyconﬁnedwithin
the nucleus. Only one tumour sample had no detectable
MGMT activity; whether or not this may have been due
to promoter methylation was not investigated. Also, we
cannot exclude the possibility that the unstained or low
MGMT-expressing cells in the examined population may be
completely or partially MGMT-promotor methylated. The
results presented here are consistent with those of other
reports examining other tumour types and showing that
staining with MGMT antibody is predominantly nuclear
[18, 19]. MGMT staining also varied markedly from one
patient to another. Whilst there was interindividual variation
in the cellular distribution of reaction, staining was present
in all cell types in most samples. In some TCC as well as SCC
cases, most of the cells expressed the protein in a relatively
homogenous pattern, whereas in others, marked intercel-
lular heterogeneity was observed. In addition, cytoplasmic6 Journal of Nucleic Acids
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Figure 5: Relationship between MGMT activity (fmole/µg of cellular DNA) and immunoﬂuorescence parameters of MGMT content (top:
%positive nuclei, middle: mean ﬂuorescence, bottom: integrated ﬂuorescence) in normal and tumour tissue.Journal of Nucleic Acids 7
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Figure 6: Relationship between tumour and normal tissue MGMT activity (fmoles/ug DNA, (a)), % positive nuclei (b), mean ﬂuorescence
(c) and integrated ﬂuorescence (d), parameters of MGMT content.
Table 2: MGMT content in bladder tumours and uninvolved tissues measured by quantitative immunoﬂuorescence.
Variable Uninvolved tissue Tumour tissue Diﬀerence tumour uninvolved P
% positive nuclei 42.8 ±13.55 7 .3 ±20.31 4 .5 ±20.5 .002
Mean ﬂuorescence 126.0 ±23.5 108.5±24.9 −17.5 ±27.1 .004
Integrated ﬂuorescence 1.9 ±1.45 .5 ±3.73 .6 ±3.5 <.001
staining of MGMT was observed in many samples with
variable intensities. Previous studies have reported a nuclear
localisation for MGMT with only occasional mention of
cytoplasmic staining [18, 20] while others reported the
presence of high levels of cytoplasmic MGMT in cancer
[21, 22]. The signiﬁcance of cytoplasmic immunoreactive
MGMT protein is unclear, but it may be that cytoplasmic
staining reﬂects a relative ineﬃciency in the ubiquitin-
mediated MGMT degradation pathway [23] giving rise to
more persistent inactive cytoplasmic protein.
The wide range of MGMT activity observed in unin-
volved tissues and bladder cancer tissues is similar to
that previously reported for bladder tissue [24–27]. In the
present study, although diﬀerences in functional activity
were observed between tumour tissue and uninvolved blad-
der tissue from the same patient when expressed per unit
protein, no diﬀerences were seen when expressed per unit
DNA. Normalisation per unit DNA is generally considered
to be more appropriate as cells vary greatly in protein
content and because MGMT acts on O6-alkylguanine lesions8 Journal of Nucleic Acids
in DNA; it also provides an indication of the number of
MGMT molecules per cell. Diﬀerences between diﬀerent
sets of published data are thus likely to reﬂect the use
of diﬀerent normalisation procedures (per unit protein or
per unit DNA). It is worth noting, however, that bladder
tumours have a very high frequency (more than 50%;
[28]) of polyploid cells, so that using DNA as a parameter,
the number of MGMT molecules per cell may be grossly
underestimated. Basing the results on either protein or DNA
content, together with the % positive nuclei or integrated
MGMT ﬂuorescence, which are indications of the overall
level of MGMT expression, would thus suggest that tumour
cells contain substantially higher levels of MGMT than
normal cells. The basis of this apparent MGMT upregulation
remains to be established.
There is a large body of evidence to suggest that MGMT
activity can be an important determinant in the eﬃcacy of
chemotherapy involving the “O6-alkylating” agents [10, 29],
and it is reasonable to consider if bladder cancer patients
might beneﬁt from such chemotherapy. There was marked
heterogeneity of MGMT distribution with, in some cases,
the majority of the tumour cells expressing relatively low
levels of MGMT. If bladder tumour patients were to be
treated with O6-alkylating agents, this would likely lead to an
initial beneﬁcial response in terms of tumour reduction, but
later, disease recurrence from those cells and areas of highest
MGMT expression. Indeed, such alkylating agents are not
used in bladder cancer treatment although a prospective
study to investigate the pretreatment expression of MGMT
and response to therapy employing appropriate alkylating
agents is feasible. Bladder cancer treatment might, however,
beneﬁt from the use of MGMT inactivating agents such
as BeG [30] or Lomeguatrib [31]w h i c hw o u l dp o t e n t i a l l y
ablate MGMT activity in bladder cells, relatively increasing
the sensitivity of the tumours cells to chemotherapy with
Temozolomide or Dacarbazine. Clinical studies of these
agents have established that MGMT activity can be depleted
by systemic administration of such agents, but this increases
the myelosuppressive eﬀect of the chemotherapeutic agent
[11]. Given our present results, intravesical administration
of MGMT inactivators prior to systemic, or even local,
chemotherapy using O6-alkylating agents seems a feasible
proposition.
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